{"symbol":"LLY","fiscalQuarter":"Q2-2026","reportDate":"2026-08-05","reportTime":"BMO","status":"upcoming","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q2-2026","estimates":{"consensusEps":6.549,"consensusRevenue":20686.28,"epsLow":5.28,"epsHigh":9.08,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Eli Lilly and Company (LLY) is a major player in the pharmaceuticals sector, focusing on innovative medicines to treat various health conditions. With a market cap of $1.03 trillion, the company is significant in the healthcare landscape, especially as it navigates the evolving demands for effective treatments and therapies.","keyMetrics":[{"name":"EPS","why":"Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.","consensus":"$6.55"},{"name":"Revenue","why":"Total revenue is essential for understanding the company's sales performance and growth trajectory.","consensus":"$20.7B"}],"lastQuarterRecap":{"summary":"In Q1 2026, Eli Lilly reported an EPS of $8.55, significantly exceeding analyst expectations of $7.06, resulting in a stock increase of 9.80% the following day. The company continues to demonstrate strong financial performance amid a competitive pharmaceutical landscape.","promises":[]},"wallStreetExpectations":{"summary":"Analysts expect Eli Lilly to report strong earnings again, with a consensus EPS of $6.55. Given the company's recent performance, there is optimism about continued revenue growth.","bullCase":"If Eli Lilly exceeds EPS expectations, it could signal robust demand for its products, potentially leading to further stock price appreciation.","bearCase":"Conversely, if the company fails to meet expectations, it may raise concerns about its growth prospects, leading to a decline in stock value."},"optionsSignal":{"impliedMove":"8.56%","context":"The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+21.07%","reaction":"+9.80%"},{"quarter":"Q4-2025","epsSurprise":"+7.88%","reaction":"+10.33%"},{"quarter":"Q3-2025","epsSurprise":"+16.59%","reaction":"+3.81%"},{"quarter":"Q2-2025","epsSurprise":"+14.08%","reaction":"-14.14%"},{"quarter":"Q1-2025","epsSurprise":"-5.01%","reaction":"-11.66%"}],"pivotalQuestions":[{"question":"Will Eli Lilly's EPS exceed the consensus estimate of $6.55?","whyItMatters":"A strong EPS could reinforce investor confidence and lead to a positive stock reaction."},{"question":"What insights will management provide regarding revenue growth trends?","whyItMatters":"Understanding revenue drivers will be critical for assessing the company's future performance and market position."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $7.00 or higher would confirm the bull case, indicating strong operational performance.","bearTrigger":"An EPS below $6.00 would confirm the bear case, raising concerns about growth sustainability.","context":"This quarter's performance is pivotal as it will either validate the company's growth trajectory or signal potential challenges ahead."},"scenarioPlaybook":{"beatAndRaise":"If Eli Lilly beats expectations, history suggests a stock increase of around 3.77%, confirming the company's strong market position.","inLineCautious":"If results are in line with expectations, the market may react cautiously, leading to muted stock movement.","miss":"A miss could result in a decline of approximately 8.97%, reflecting investor disappointment and concerns about future growth."},"whatTheStreetIsMissing":{"thesis":"The consensus may underestimate Eli Lilly's ability to leverage recent product launches, which could drive higher-than-expected revenue growth.","supportingPoints":["Eli Lilly has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.","The options market is pricing in a significant move, suggesting that investors expect volatility based on potential surprises."],"riskToConsensus":"If revenue growth exceeds $21B, it could challenge the current bearish sentiment and shift market expectations."},"whatToListenFor":["Any updates on new product launches and their expected market impact.","Details on cost management strategies and their effect on margins.","Insights into competitive pressures and how Eli Lilly plans to address them.","Management's outlook on market conditions and potential regulatory impacts.","Any commentary on long-term growth strategies and pipeline developments."],"metaDescription":"Eli Lilly (LLY) reports Q2 2026 earnings August 5. Analysts expect $6.55 EPS on $20.7B revenue. Here's what to watch."}}